Teva, Active Biotech to begin Phase III study of Oral Laquinimod
07:12 EDT 10 Aug 2012 | Pharmaceutical Business Review
Teva Pharmaceutical Industries and Active Biotech will initiate third Phase III study of Oral Laquinimod for the treatment of relapsing remitting multiple sclerosis.
Original Article: Teva, Active Biotech to begin Phase III study of Oral Laquinimod
More From BioPortfolio on "Teva, Active Biotech to begin Phase III study of Oral Laquinimod"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
